Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence

References

• Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372(9639):657–668.
   PubMed Web of Science ®Google Scholar
• Salido-Vallejo R, Garnacho-Saucedo G, Moreno-Giménez JC. Current options for the treatment of facial angiofibromas. Actas Dermosifiliogr. 2014;105(6):558–568.
   PubMedGoogle Scholar
• Jóźwiak S, Sadowski K, Kotulska K, et al. Topical use of mammalian target of rapamycin (mTOR) inhibitors in tuberous sclerosis complex-a comprehensive review of the literature. Pediatr Neurol. 2016;61:21–27.
   PubMed Web of Science ®Google Scholar
• Narayanan V. Tuberous sclerosis complex: genetics to pathogenesis. Pediatr Neurol. 2003;29(5):404–409.
   PubMed Web of Science ®Google Scholar
• Balestri R, Neri I, Patrizi A, et al. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex. J Eur Acad Dermatol Venereol. 2015;29(1):14–20.
   PubMed Web of Science ®Google Scholar
• Rumsey N, Clarke A, White P. Exploring the psychosocial concerns of outpatients with disfiguring conditions. J Wound Care. 2003;12(7):247–252.
   PubMedGoogle Scholar
• Zweegers J, van der Vleuten CJ. The psychosocial impact of an infantile haemangioma on children and their parents. Arch Dis Child. 2012;97(10):922–926.
   PubMed Web of Science ®Google Scholar
• Patrick DL, Topolski TD, Edwards TC, et al. Measuring the quality of life of youth with facial differences. Cleft Palate Craniofac J. 2007;44(5):538–547.
   PubMed Web of Science ®Google Scholar
• Biondo G, Greco S, Mavilia L, et al. Treatment of nodular facial angiofibromas in tuberous sclerosis, using ultrapulse carbon dioxide laser. Clin Exp Dermatol. 2014;39(6):738–740.
   PubMed Web of Science ®Google Scholar
• Leducq S, Giraudeau B, Tavernier E, et al. Topical use of mammalian target of rapamycin inhibitors in dermatology: a systematic review with meta-analysis. J Am Acad Dermatol. 2019;80(3):735–742.
   PubMed Web of Science ®Google Scholar
• Hofbauer GF, Marcollo-Pini A, Corsenca A, et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol. 2008;159(2):473–475.
   PubMed Web of Science ®Google Scholar
• Tarasewicz A, Debska-Slizien A, Konopa J, et al. Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. Transplant Proc. 2009;41(9):3677–3682.
   PubMed Web of Science ®Google Scholar
• Micozkadioglu H, Koc Z, Ozelsancak R, et al. Rapamycin therapy for renal, brain, and skin lesions in a tuberous sclerosis patient. Ren Fail. 2010;32(10):1233–1236.
   PubMed Web of Science ®Google Scholar
• Haemel AK, O'Brian AL, Teng JM. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol. 2010;146(7):715–718.
   PubMedGoogle Scholar
• Wheless MC, Takwi AA, Almoazen H, Wheless JW. Long-term exposure and safety of a novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex: results from a single-center, open-label trial. Child Neurol Open. 2019;6:2329048X19835047.
   PubMedGoogle Scholar
• Okanishi T, Fujimoto A, Enoki H, et al. Early sirolimus gel treatment may diminish angiofibromas and prevent angiofibroma recurrence in children with tuberous sclerosis complex. Front Med. 2020;7:1.
   Web of Science ®Google Scholar
• Salido-Vallejo R, Ruano J, Garnacho-Saucedo G, et al. Facial Angiofibroma Severity Index (FASI): reliability assessment of a new tool developed to measure severity and responsiveness to therapy in tuberous sclerosis-associated facial angiofibroma. Clin Exp Dermatol. 2014;39(8):888–893.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services. Centers for Disease Control and Prevention National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings. 2014. [cited 2019 Jun 19]. Available in: https://www.cdc.gov/niosh/docs/2014-138/pdfs/2014-138.pdf.
   Google Scholar
• U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894. MeSH Terms. [cited 2019 Jun 19]. Available in: https://meshb.nlm.nih.gov/search. 2018.
   Google Scholar
• Howick J. Centre for Evidence-Based Medicine (Oxford). Levels of evidence, Oxford Centre for Evidence-based Medicine. 2009. [cited 2019 Jun 19]. Available in: https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/.
   Google Scholar
• Koenig MK, Hebert AA, Roberson J, et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin. Drugs R D. 2012;12(3):121–126.
   PubMedGoogle Scholar
• Wataya-Kaneda M, Nakamura A, Tanaka M, et al. Efficacy and safety of topical sirolimus therapy for facial angiofibromas in the tuberous sclerosis complex: a randomized clinical trial. JAMA Dermatol. 2017;153(1):39–48.
   PubMed Web of Science ®Google Scholar
• Koenig MK, Bell CS, Hebert AA, et al. Efficacy and safety of topical rapamycin in patients with facial angiofibromas secondary to tuberous sclerosis complex: The TREATMENT Randomized Clinical Trial. JAMA Dermatol. 2018;154(7):773–780.
   PubMed Web of Science ®Google Scholar
• Chen PL, Hong JB, Shen LJ, et al. The efficacy and safety of topical rapamycin-calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double-blind, randomized clinical trial. Br J Dermatol. 2020;183(4):655–663.
   PubMed Web of Science ®Google Scholar
• Wataya-Kaneda M, Tanaka M, Nakamura A, et al. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity. Br J Dermatol. 2011;165(4):912–916.
   PubMed Web of Science ®Google Scholar
• Mutizwa MM, Berk DR, Anadkat MJ. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1)) in two patients with tuberous sclerosis. Br J Dermatol. 2011;165(4):922–923.
   PubMed Web of Science ®Google Scholar
• Salido R, Garnacho-Saucedo G, Cuevas-Asencio I, et al. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis – associated facial angiofibroma. J Eur Acad Dermatol Venereol. 2012;26(10):1315–1318.
   PubMed Web of Science ®Google Scholar
• Kaufman McNamara E, Curtis AR, Fleischer AB. Jr. Successful treatment of angiofibromata of tuberous sclerosis complex with rapamycin. J Dermatolog Treat. 2012;23(1):46–48.
   PubMed Web of Science ®Google Scholar
• Foster RS, Bint LJ, Halbert AR. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients. Australas J Dermatol. 2012;53(1):52–56.
   PubMed Web of Science ®Google Scholar
• Wheless JW, Almoazen H. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex. J Child Neurol. 2013;28(7):933–936.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Wataya-Kaneda M, Nakamura A, et al. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex. Br J Dermatol. 2013;169(6):1314–1318.
   PubMed Web of Science ®Google Scholar
• Tu J, Foster RS, Bint LJ, et al. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions. Australas J Dermatol. 2014;55(1):63–69.
   PubMed Web of Science ®Google Scholar
• Park J, Yun SK, Cho YS, et al. Treatment of angiofibromas in tuberous sclerosis complex: the effect of topical rapamycin and concomitant laser therapy. Dermatology. 2014;228(1):37–41.
   PubMed Web of Science ®Google Scholar
• Pynn EV, Collins J, Hunasehally PR, et al. Successful topical rapamycin treatment for facial angiofibromata in two children. Pediatr Dermatol. 2015;32(3):e120–e123.
   PubMed Web of Science ®Google Scholar
• Cinar SL, Kartal D, Bayram AK, et al. Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis. Indian J Dermatol Venereol Leprol. 2017;83(1):27–32.
   PubMed Web of Science ®Google Scholar
• Wang S, Liu Y, Wei J, et al. Tuberous sclerosis complex in 29 children: clinical and genetic analysis and facial angiofibroma responses to topical sirolimus. Pediatr Dermatol. 2017;34(5):572–577.
   PubMed Web of Science ®Google Scholar
• Amin S, Lux A, Khan A, et al. Sirolimus ointment for facial angiofibromas in individuals with tuberous sclerosis complex. Int Sch Res Notices. 2017;2017:8404378.
   PubMedGoogle Scholar
• Lee YI, Lee JH, Kim DY, et al. Comparative effects of topical 0.2% sirolimus for angiofibromas in adults and pediatric patients with tuberous sclerosis complex. Dermatology. 2018;234(1–2):13–22.
   PubMed Web of Science ®Google Scholar
• Hatano T, Ohno Y, Imai Y, et al. Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex. Orphanet J Rare Dis. 2020;15(1):133.
   PubMed Web of Science ®Google Scholar
• DeKlotz CM, Ogram AE, Singh S, et al. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol. Arch Dermatol. 2011;147(9):1116–1117.
   PubMedGoogle Scholar
• Truchuelo T, Diaz-Ley B, Rios L, et al. Facial angiofibromas treated with topical rapamycin: an excellent choice with fast response. Dermatol Online J. 2012;18(1):15.
   PubMedGoogle Scholar
• Bae-Harboe YS, Geronemus RG. Targeted topical and combination laser surgery for the treatment of angiofibromas. Lasers Surg Med. 2013;45(9):555–557.
   PubMed Web of Science ®Google Scholar
• Knopfel N, Martin-Santiago A, Bauza A, et al. Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis. Actas Dermosifiliogr. 2014;105(8):802–803.
   PubMedGoogle Scholar
• Tiedemann Svendsen M, Bygum A, Hansen LK, et al. Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus. Ugeskr Laeger. 2013;175(43):2569–2570.
   PubMedGoogle Scholar
• Schwartz RA. Facial angiofibromas of tuberous sclerosis treated with topical sirolimus in an Indian patient (commentary on article by Resham J. Vasani). Dermatol Ther. 2016;29(1):70–71.
   PubMed Web of Science ®Google Scholar
• Ebrahimi-Fakhari D, Muller CSL, Meyer S, et al. Topical rapamycin for facial angiofibromas in a child with tuberous sclerosis complex (TSC): a case report and long-term follow-up. Dermatol Ther. 2017;7(1):175–179.
   Web of Science ®Google Scholar
• Negosanti F, Tengattini V, Gurioli C, et al. Facial angiofibromas treated by rapamycin 0.05% ointment and a combined laser therapy. J Cosmet Dermatol. 2018;17(5):762–765.
   PubMed Web of Science ®Google Scholar
• Crall C, Valle M, Kapur K, et al. Effect of angiofibromas on quality of life and access to care in tuberous sclerosis patients and their caregivers. Pediatr Dermatol. 2016;33(5):518–525.
   PubMed Web of Science ®Google Scholar
• Lewis-Jones MS, Finlay AY. The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol. 1995;132(6):942–949.
   PubMed Web of Science ®Google Scholar
• Smidt AC, Lai JS, Cella D, et al. Development and validation of Skindex-Teen, a quality-of-life instrument for adolescents with skin disease. Arch Dermatol. 2010;146(8):865–869.
   PubMedGoogle Scholar
• Chamlin SL, Lai JS, Cella D, et al. Childhood Atopic Dermatitis Impact Scale: reliability, discriminative and concurrent validity, and responsiveness. Arch Dermatol. 2007;143(6):768–772.
   PubMedGoogle Scholar
• Brown MM, Chamlin SL, Smidt AC. Quality of life in pediatric dermatology. Dermatol Clin. 2013;31(2):211–221.
   PubMed Web of Science ®Google Scholar
• Ramien ML, Ondrejchak S, Gendron R, et al. Quality of life in pediatric patients before and after cosmetic camouflage of visible skin conditions. J Am Acad Dermatol. 2014;71(5):935–940.
   PubMed Web of Science ®Google Scholar
• Lilly E, Lu PD, Borovicka JH, et al. Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol. 2013;69(1):e11–e18.
   PubMed Web of Science ®Google Scholar